OBJECTIVE: To investigate whether the addition of grip strength and/or self-reported walking pace to established cardiovascular disease (CVD) risk scores improves their predictive abilities. PATIENTS AND METHODS: A total of 406,834 participants from the UK Biobank, with baseline measurements between March 13, 2006, and October 1, 2010, without CVD at baseline were included in this study. Associations of grip strength and walking pace with CVD outcomes were investigated using Cox models adjusting for classical risk factors (as included in established risk scores), and predictive utility was determined by changes in C-index and categorical net reclassification index. RESULTS: Over a median of 8.87 years of follow-up (interquartile range 3, 8.25-9.47 years), there were 7274 composite fatal/nonfatal events (on the basis of the American College of Cardiology/American Heart Association [ACC/AHA] outcome) and 1955 fatal events (on the basis of the Systematic Coronary Risk Evaluation [SCORE] risk score). Both grip strength and walking pace were inversely associated with CVD outcomes after adjusting for classical risk factors. Addition of grip strength (change in C-index: ACC/AHA, +0.0017; SCORE, +0.0047), usual walking pace (ACC/AHA, +0.0031; SCORE, +0.0130), and both combined (ACC/AHA, +0.0041; SCORE, +0.0148) improved the C-index and also improved the net reclassification index (grip, +0.55%; walking pace, +0.53%; combined, 1.12%). CONCLUSION: The present study has found that the addition of grip strength or usual walking pace to existing risk scores results in improved CVD risk prediction, with an additive effect when both are added. As both these measures are cheap and easy to administer, these tools could provide an important addition to CVD risk screening, although further external validation is required.
OBJECTIVE: To investigate whether the addition of grip strength and/or self-reported walking pace to established cardiovascular disease (CVD) risk scores improves their predictive abilities. PATIENTS AND METHODS: A total of 406,834 participants from the UK Biobank, with baseline measurements between March 13, 2006, and October 1, 2010, without CVD at baseline were included in this study. Associations of grip strength and walking pace with CVD outcomes were investigated using Cox models adjusting for classical risk factors (as included in established risk scores), and predictive utility was determined by changes in C-index and categorical net reclassification index. RESULTS: Over a median of 8.87 years of follow-up (interquartile range 3, 8.25-9.47 years), there were 7274 composite fatal/nonfatal events (on the basis of the American College of Cardiology/American Heart Association [ACC/AHA] outcome) and 1955 fatal events (on the basis of the Systematic Coronary Risk Evaluation [SCORE] risk score). Both grip strength and walking pace were inversely associated with CVD outcomes after adjusting for classical risk factors. Addition of grip strength (change in C-index: ACC/AHA, +0.0017; SCORE, +0.0047), usual walking pace (ACC/AHA, +0.0031; SCORE, +0.0130), and both combined (ACC/AHA, +0.0041; SCORE, +0.0148) improved the C-index and also improved the net reclassification index (grip, +0.55%; walking pace, +0.53%; combined, 1.12%). CONCLUSION: The present study has found that the addition of grip strength or usual walking pace to existing risk scores results in improved CVD risk prediction, with an additive effect when both are added. As both these measures are cheap and easy to administer, these tools could provide an important addition to CVD risk screening, although further external validation is required.
Authors: Fanny Petermann-Rocha; Viktoria Balntzi; Stuart R Gray; Jose Lara; Frederick K Ho; Jill P Pell; Carlos Celis-Morales Journal: J Cachexia Sarcopenia Muscle Date: 2021-11-23 Impact factor: 12.910
Authors: Verónica Cabanas-Sánchez; Irene Esteban-Cornejo; Solange Parra-Soto; Fanny Petermann-Rocha; Stuart R Gray; Fernando Rodríguez-Artalejo; Frederick K Ho; Jill P Pell; David Martínez-Gómez; Carlos Celis-Morales Journal: J Cachexia Sarcopenia Muscle Date: 2022-06-08 Impact factor: 12.063
Authors: Xiao Hu; Yejin Mok; Ning Ding; Kevin J Sullivan; Pamela L Lutsey; Jennifer A Schrack; Priya Palta; Kunihiro Matsushita Journal: J Am Heart Assoc Date: 2022-08-31 Impact factor: 6.106
Authors: Solange Parra-Soto; Jill P Pell; Carlos Celis-Morales; Frederick K Ho Journal: J Cachexia Sarcopenia Muscle Date: 2021-12-24 Impact factor: 12.063
Authors: Fanny Petermann-Rocha; Lyn D Ferguson; Stuart R Gray; Irene Rodríguez-Gómez; Naveed Sattar; Stefan Siebert; Frederick K Ho; Jill P Pell; Carlos Celis-Morales Journal: J Cachexia Sarcopenia Muscle Date: 2021-07-15 Impact factor: 12.910
Authors: Frederick K Ho; Stuart Robert Gray; Carlos Celis-Morales; Jirapitcha Boonpor; Solange Parra-Soto; Fanny Petermann-Rocha; Gerson Ferrari; Paul Welsh; Jill P Pell; Naveed Sattar; Jason Martin Regnald Gill Journal: BMJ Open Diabetes Res Care Date: 2021-08